+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area



Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area



Indian Journal of Ophthalmology 65(1): 48-51



Context (Background): Imiquimod (IMQ) 5% cream is an immunomodulatory and antitumorigenic agent, which was used as a topical treatment regimen, who had periocular basal cell carcinoma (BCC). This study aims to present three cases with large BCC at the medial canthal area treated with IMQ 5% cream. IMQ 5% cream was used in three patients with ages 45, 49, and 73 who preferred medical treatment over surgery. Following incisional biopsy IMQ cream was used once a day, 5 times a week and the patients were followed up weekly during 12 week treatment period and monthly after the clearance of the lesion. Erythema and erosion on the surface of the lesion, injection of conjunctiva, burning and itching sensation, epiphora and punctate keratitis were seen in all patients during the treatment period. The ophthalmic side effects could be managed by topical lubricating eye drops and the inflammatory reactions resolved within 1 month after cessation of therapy. The patients were followed up for at least 3 years without tumor recurrence and the biopsies taken from the suspected area were found to be tumor free. Surgical excision of carcinoma of the eyelid at medial canthal area can be difficult without causing damage to the lacrimal system and reconstruction of the defect may need grafts or flaps. IMQ may provide an alternative therapy to surgery in certain cases.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 059831580

Download citation: RISBibTeXText

PMID: 28300740


Related references

Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma. Dermatology Nursing 21(2): 86-87, 2009

Imiquimod 5% Cream as Pre-Treatment of Mohs Micrographic Surgery for Nodular Basal Cell Carcinoma in the Face, A Prospective Randomized Controlled Study Imiquimod As Pre-Treatment of Mohs. 2012

Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial. Bmc Ophthalmology 15: 35, 2015

Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream. Dermatology Online Journal 14(2): 25, 2008

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology 138(9): 1165-1171, 2002

Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. Journal of Drugs in Dermatology 6(9): 910-914, 2007

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology 147(6): 1227-1236, 2002

5% imiquimod cream for the treatment of large superficial basal cell carcinoma. Archives of Dermatology 140(10): 1286-1287, 2004

An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australasian Journal of Dermatology 47(1): 46-48, 2006

Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. American Journal of Ophthalmology 140(6): 1136-1139, 2005

Imiquimod 5% cream as an adjuvant pre-operative treatment for basal cell carcinoma of the periocular area. Orbit 33(6): 471-473, 2014

Resolution of tinea pedis with imiquimod cream 5% in a patient with nodular basal cell carcinoma. Cutis 78(1): 66-69, 2006

Ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream. Journal of Drugs in Dermatology 10(3): 240-241, 2011

Basal cell carcinoma of the medial canthal area. Plastic and Reconstructive Surgery 55(6): 667-676, 1975

A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology 57(4): 616-621, 2007